Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbrella Study of Recurrent ES-SCLC Based on Molecular Typing
NCT07141771Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of serplulimab, fluzoparib in small cell lung cancer (SCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
serplulimabfluzoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07141771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141771.